Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Bleeding Disorders

17 April 2009 CSL Behring Marks World Hemophilia Day with $2M Coagulation Factor Donation to World Federation of Hemophilia

In recognition of the World Federation of Hemophilia’s (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program, CSL Behring has committed to donating to WFH two (2) million units of factor VIII concentrate (FVIII) each year for the next three (3) years. The donation, the total value of which will be approximately $2 million, will be made using coagulation factor concentrate with a minimum shelf-life of one year.

> Read More
02 April 2009 CSL Behring to Launch Next GameFaces™ Program Challenge

CSL Behring announced it will hold its next GameFaces™ challenge from April 14 through July 7, 2009. GameFaces is a family-oriented, online initiative for people with hemophilia A. The program is designed to encourage real-life physical activity through a series of customized challenges based on the individual’s age, disease severity and current level of physical activity.

> Read More
16 January 2009 CSL Behring Receives FDA Approval of RiaSTAP™, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP™, the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Congenital fibrinogen deficiency is a rare, potentially life-threatening bleeding disorder that affects an estimated one person per million, with an estimated prevalence in the U.S. of approximately 300 patients. RiaSTAP is not indicated to treat dysfibrinogenemia.

> Read More
19 November 2008 CSL Behring Launches GameFaces Program at National Hemophilia Foundation Annual Meeting

CSL Behring announced today it launched the first challenge of GamesFaces™, a family-oriented online initiative for patients with hemophilia A, at the 60th Annual Meeting of the National Hemophilia Foundation (NHF). GameFaces is designed to encourage real-life physical activity through a series of three customized challenges based on the individual’s age, disease severity and current level of physical activity. Participants can now log on to the program website at www.HFSGameFaces.com, create their GameFaces character and begin the first challenge, which will run from today through January 10, 2009.

> Read More
01 October 2008 Moms Raise "Red Flag" about the Dangers of Widely Undiagnosed Bleeding Disorder

National Campaign Highlights Signs, Symptoms, Impact on Families of von Willebrand Disease. A group of mothers with VWD have joined together to focus attention on the need for more communication between mothers and their children about signs, symptoms and potentially severe health consequences of this disease.

> Read More
Page 18 of 20 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+